Fate Therapeutics Inc
FATE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001434316
In the last 90 days, Fate Therapeutics Inc insiders filed 0 open-market purchases and 2 sales; 156 institutions reported holding it in 13F filings for Q2 2026, worth $193.6M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $203.5K in total
- 2
- 13F holdersQ2 2026, +1 vs. previous quarter
- 156
- 13F valueReported value at the end of Q2 2026
- $193.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding FATE, Q2 2026
No superinvestor reported holding FATE at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Fate Therapeutics Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 5, 2026 (view filing)4:03 PM ET | Aug 4 | 1 day | Tahl CindySee Remarks | SSale | −38.8K | $2.46 | −$95.4K | −6.2%589.4K after | |
| Aug 5, 2026 (view filing)4:01 PM ET | Aug 4 | 1 day | Valamehr BahramPresident and CEO | SSale | −43.9K | $2.46 | −$108.1K | −6.9%591.8K after | |
| May 21, 2026 (view filing) | May 20 | 1 day | Tahl CindySee Remarks | SSale | −25.6K | $1.88 | −$48.1K | −3.9%628.2K after | |
| May 21, 2026 (view filing) | May 20 | 1 day | Valamehr BahramPresident and CEO | SSale | −28.9K | $1.88 | −$54.4K | −4.4%635.8K after | |
| Jan 12, 2026 (view filing) | Jan 9 | 3 days | Tahl CindySee Remarks | SSale | −10.6K | $1.06 | −$11.2K | −2.7%387.1K after | |
| Jan 12, 2026 (view filing) | Jan 9 | 3 days | Valamehr BahramPresident and CEO | SSale | −5.19K | $1.07 | −$5.55K | −1.5%329.7K after | |
| Aug 5, 2025 (view filing) | Aug 4 | 1 day | Tahl CindySee Remarks | SSale | −9.04K | $1.06 | −$9.58K | −2.2%397.7K after | |
| Aug 5, 2025 (view filing) | Aug 4 | 1 day | Valamehr BahramPresident and CEO | SSale | −14.5K | $1.06 | −$15.3K | −4.1%334.9K after | |
| Jan 13, 2025 (view filing) | Jan 10 | 3 days | Bressi Jerome CharlesSee Remarks | SSale | −5.98K | $1.55 | −$9.27K | −2.2%270.2K after | |
| Jan 13, 2025 (view filing) | Jan 10 | 3 days | Tahl CindySee Remarks | SSale | −5.65K | $1.55 | −$8.76K | −1.7%336.7K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Fate Therapeutics Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Redmile Group, LLC | 12,872,946 | $34.8M | 2.33% | 00.0% | Unchanged |
| BlackRock, Inc. | 7,298,895 | $19.7M | 0.00% | −2,769,719−27.5% | Reduced |
| Vanguard Portfolio Management LLC | 4,545,893 | $12.3M | 0.00% | +411,308+9.9% | Added |
| Vanguard Capital Management LLC | 4,445,536 | $12.0M | 0.00% | +253,473+6.0% | Added |
| Acadian Asset Management LLC | 4,351,250 | $11.7M | 0.01% | +231,050+5.6% | Added |
| AQR Capital Management LLC | 3,837,229 | $10.4M | 0.00% | +835,708+27.8% | Added |
| Two Sigma Investments, LP | 3,589,863 | $9.69M | 0.01% | +123,077+3.6% | Added |
| Johnson & Johnson | 3,379,064 | $9.12M | 1.14% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 2,983,268 | $8.05M | 0.01% | +8,585+0.3% | Added |
| Millennium Management LLC | 2,433,978 | $6.57M | 0.00% | +2,433,978 | New |